Endo Health new CEO suggests near-term sale unlikely, says Wells Fargo Wells Fargo believes the appointment of new CEO Rajiv De Silva suggests Endo Health does not intend to sell itself in the near-term, contrary to a Reuters report in January. Wells has a Market Perform rating on Endo shares.
Endo rallies amid talk of conference cancellation Shares of Endo International are rallying 2% amid talk the company cancelled out of Leerink's conference next week. Endo has no events listed on its website and Bloomberg just reported that according to sources, the company cancelled its appearance at the conference. Shares of Endo are up $1.25 to $55.40 in afternoon trading.